Human Longevity

Primary contact

Human Longevity, Inc. (HLI) is revolutionizing human health by generating more data and deeper understanding into what can keep you living healthier longer. HLI's scientists have created the world's largest database of sequenced genomes and phenotypic (physical traits) data, to uncover unprecedented insights capable of transforming healthcare from reactive to proactive. The company combines state-of-the-art DNA sequencing and expert analysis with machine learning, to help change medicine to a more data-driven science. Its flagship offering, the Health Nucleus advanced clinical research platform, is designed to assess your current health state and your potential health risks. The platform relies on HLI's proprietary technology to identify actionable opportunities to empower patients and their physicians to take control of their health and proactively plan for a longer healthy life. The system offers whole genome sequencing to provide patients with insights into their genetic risks for clinical, health, personal and physical insights. In addition, an advanced, high definition MRI scan can detect some cancers, lipid abnormalities, neuro-degeneration, and neurovascular disease; while Microbiome sequencing can gives clients an analysis of microorganisms that reside in the gastrointestinal tract and describe how they may impact their health. Finally, depending on the Health Nucleus service clients choose, they may have other health tests such as CT Scan, cardiac rhythm monitoring, 4D echocardiogram, metabolome, or lab analyses.
Primary contact

Funding 💰

Total $300M
Select investors Illumina, Amino Capital, Celgene, Draper Fisher Jurvetson, GE Ventures, StartUp Health, OS Fund
Last update: April 1, 2018